Prebona (PREBON) Q4 2024 earnings summary

Executive summary

• Net sales for Q4 2024 were SEK 1.12 million, down from SEK 2.35 million year-over-year; full-year net sales were SEK 5.68 million, down from SEK 8.49 million.

• Q4 result after financial items improved to SEK -1.34 million from SEK -1.87 million; full-year result after financial items was SEK -7.21 million, compared to SEK -5.96 million.

• Key business milestones include Inodorus® registration in Norway's insurance system, a first order from Boots Apotek, and a stoma tender win in Västra Götalandsregionen.

• Positive patent news from the European Patent Office and promising test results for AgSol in enhancing antibiotic efficacy.

• A directed share issue of approximately SEK 5 million was completed after the period to support sales and marketing efforts.

Financial highlights

• Q4 operating income was SEK 1.47 million (SEK 2.39 million prior year); full-year operating income was SEK 6.29 million (SEK 8.91 million prior year).

• Q4 cash flow from operations was SEK -2.26 million (SEK -1.91 million prior year); full-year cash flow from operations was SEK -5.94 million (SEK -4.67 million prior year).

• Earnings per share for Q4 were SEK -0.05 (SEK -0.07 prior year); full-year EPS was SEK -0.25 (SEK -0.22 prior year).

• Number of shares at period end: 29,216,729 (26,616,254 prior year).

• Solidarity ratio at year-end was approximately 11%.

Outlook and guidance

• Management expects sales increases in coming quarters due to ongoing sales activities and new product commercialization.

• The board believes available liquidity and new share issues will finance operations for the next 12 months; further strategic initiatives may require additional funding.

• Focus remains on achieving positive cash flow and strengthening market presence in prioritized geographies.